What it's for (Indications)
- The varicella virus vaccine is indicated for active immunization for the prevention of varicella (chickenpox) disease in individuals 12 months of age and older.
- This live, attenuated virus vaccine is crucial for establishing long-term immunity against the varicella-zoster virus (VZV).
- It is recommended for routine childhood immunization, as well as for catch-up vaccination for susceptible adolescents and adults who have not previously had chickenpox or been vaccinated.
- The primary goal is to reduce the incidence of varicella, its associated complications, including severe disease, hospitalization, and death, and to limit viral transmission within communities, thereby protecting vulnerable populations who cannot be vaccinated.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for the varicella virus vaccine is 0.5 mL administered subcutaneously. For children aged 12 months to 12 years, the primary vaccination schedule consists of two doses. The first dose is typically given at 12 to 15 months of age, followed by a second dose at 4 to 6 years of age. For adolescents (13 years of age and older) and adults, two doses are required, with the second dose administered 4 to 8 weeks after the first dose, ensuring a minimum interval of 4 weeks between doses. It is imperative to adhere to the prescribed dosing schedule and route of administration to ensure optimal immune response and protection against the varicella-zoster virus. |
Safety & Warnings
Common Side Effects
- The varicella virus vaccine is generally well-tolerated, with most side effects being mild and transient.
- Common reactions at the injection site include pain, soreness, redness, and swelling.
- Systemic reactions may include fever (low-grade), irritability, and a mild, varicella-like rash, which typically consists of a few lesions and is self-limiting.
- Less common but more serious adverse events can occur, such as febrile seizures, severe allergic reactions (anaphylaxis), aseptic meningitis, pneumonia, and thrombocytopenia.
- While rare, these serious events underscore the importance of post-vaccination observation and prompt medical attention for any concerning symptoms.
- Healthcare providers should counsel patients on potential adverse reactions and when to seek medical advice.
Serious Warnings
- Black Box Warning: While the varicella virus vaccine does not carry an FDA-mandated Black Box Warning, several critical safety considerations warrant serious attention. Healthcare providers must recognize that administration to immunocompromised individuals, including those with primary or acquired immunodeficiency or those on immunosuppressive therapy, carries a significant risk of disseminated vaccine-strain varicella disease, which can be severe or fatal. Therefore, a thorough assessment of immune status is imperative before vaccination. The vaccine is contraindicated in pregnancy due to potential fetal harm, and women of childbearing age must be advised to avoid conception for at least one month after vaccination. Furthermore, anaphylactic reactions can occur, necessitating immediate availability of epinephrine and appropriate medical support. There is also a theoretical, albeit low, risk of vaccine virus transmission from vaccinated individuals with rash to susceptible, high-risk contacts, particularly those who are severely immunocompromised. Patients should be cautioned against salicylate use for six weeks post-vaccination due to the theoretical risk of Reye's Syndrome following wild-type varicella infection.
- Healthcare providers should exercise caution when administering the varicella virus vaccine.
- Individuals with a history of severe allergic reaction (e.
- g.
- , anaphylaxis) to any component of the vaccine or to a previous dose should not receive it.
- Live attenuated vaccines carry a theoretical risk of transmission of the vaccine virus from a vaccinated individual to susceptible contacts, particularly those who are immunocompromised; however, this risk is very low.
- Temporary deferral of vaccination is advised for individuals with an acute severe febrile illness.
- The vaccine should not be administered to pregnant women due to the theoretical risk to the fetus, and women should be advised to avoid pregnancy for at least one month after vaccination.
- Close monitoring is recommended for individuals with a history of thrombocytopenia due to a potential for exacerbation.
How it Works (Mechanism of Action)
The varicella virus vaccine is a live, attenuated vaccine derived from the Oka strain of the varicella-zoster virus (VZV). Its mechanism of action involves stimulating an active immune response without causing clinical disease. Upon subcutaneous administration, the attenuated virus replicates in the host, mimicking a natural, mild infection. This replication induces both humoral and cell-mediated immune responses. Specifically, it stimulates the production of VZV-specific antibodies, including IgG, and activates VZV-specific T lymphocytes. These immune responses are crucial for developing immunological memory, which provides long-term protection against subsequent exposure to the wild-type varicella-zoster virus, thereby preventing or significantly attenuating chickenpox disease. The attenuation process reduces virulence while maintaining immunogenicity.
Commercial Brands (Alternatives)
No other brands found for this formula.